HEBP2 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HAP1 cell line. This product provides a loss-of-function model of the HEBP2 gene, which encodes a heme-binding protein implicated in heme trafficking and apoptotic regulation. The polyclonal format ensures a heterogeneous editing profile, enabling robust population-level analyses of HEBP2 function. This gene-targeted cell pool is suitable for researchers investigating heme metabolism and oxidative stress-mediated cell death pathways.
The HAP1 cell line is a near-haploid human cell line originally derived from the KBM-7 chronic myeloid leukemia line. Its near-haploid karyotype simplifies genetic manipulation and analysis, making it a widely used model for functional genomics and cancer research. HAP1 cells retain key features of CML, including dependence on specific signaling pathways, and provide a tractable system for studying gene function in a leukemic context. The combination of HAP1??s genetic tractability with HEBP2 disruption offers a powerful tool for dissecting heme-related processes in malignant cells.
HEBP2 (heme-binding protein 2) is thought to participate in intracellular heme trafficking and detoxification, and may influence apoptosis by interacting with heme and other heme-binding proteins. The mechanistic summary indicates that loss of HEBP2 disrupts heme binding and potentially alters cellular responses to heme-induced oxidative stress and apoptotic signals. HEBP2 is connected to the BCL2 family and cytochrome c, key regulators of mitochondrial apoptosis. While direct upstream regulators and downstream targets remain unknown, HEBP2 likely functions within heme metabolism and apoptosis networks, potentially modulating the release of cytochrome c or the activity of BCL2 family members in response to heme levels.
In HAP1 CML cells, HEBP2 knockout may reveal defective handling of heme, leading to aberrant oxidative stress responses or altered apoptotic thresholds. As heme is both a cofactor and a signaling molecule, its dysregulation can contribute to leukemic cell survival and drug resistance. This knockout model allows dissection of HEBP2??s role in maintaining redox balance and apoptosis regulation in a leukemic background, providing insights into potential vulnerabilities of CML cells. Coupled with HAP1??s ploidy advantage, the polyclonal population enables functional screens to identify genetic interactions and chemical sensitivities linked to heme metabolism and apoptosis.
Researchers can employ HEBP2 Knockout HAP1 Polyclonal Cells in a range of assays, including Western blotting and RT-qPCR to confirm gene disruption and assess downstream targets, apoptosis and oxidative stress assays to evaluate functional consequences of knockout, heme-binding assays to quantify altered heme interactions, and flow cytometry for phenotypic profiling. These cells are valuable for studying heme trafficking pathways, oxidative stress responses in cancer, and for drug target identification in leukemia. For further details, please contact Ascent Research.
